Minoxidil vs PTD-DBM
A side-by-side research comparison of Minoxidil and PTD-DBM across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Minoxidil | PTD-DBM |
|---|---|---|
| Full name | Minoxidil (Rogaine) | PTD-DBM (Wnt Pathway Hair Peptide) |
| Category | Hair Growth | Hair Growth |
| Status | FDA Approved (OTC) | Research peptide (topical) |
| Mechanism | Opens ATP-sensitive potassium channels in vascular smooth muscle and hair follicle cells. Increases blood flow and nutrient delivery to follicles. Prolongs anagen (growth) phase and stimulates VEGF expression for neovascularization around follicles. | PTD-DBM disrupts the interaction between CXXC5 and Dishevelled, releasing a natural brake on the Wnt/beta-catenin signaling pathway. Enhanced Wnt signaling promotes hair follicle neogenesis and regeneration. |
| Molecular weight | 209.25 Da | ~ (short cell-penetrating peptide) |
| Half-life | ~4 hours (systemic); active in follicle for 22h | Topical (local action) |
| Bioavailability | ~95% oral; topical: local depot effect | Topical (local delivery) |
| Typical dose | 5% topical (1mL 2x/day) or 2.5-5 mg oral | Topical scalp application (research) |
| Frequency | Twice daily (topical) or once daily (oral) | Daily |
| Route | Topical solution/foam or oral tablet | Topical |
Minoxidil reported benefits
- Stimulates new hair growth
- Works independently of DHT pathway
- OTC availability
- Effective for both sexes
- Prolongs anagen phase
- Can combine with any other treatment
PTD-DBM reported benefits
- Activates Wnt/beta-catenin hair pathway
- Promotes follicle neogenesis (research)
- Synergy with valproic acid
- Non-hormonal hair mechanism
Related comparisons
Research and educational reference only. Not medical advice.